Compare medications

Max 4 meds. Sources include DailyMed labels; verify against official labeling. Last reviewed shown per row. On small screens the table defaults to a compact view—use “Show all columns” to view everything (scroll horizontally). Visit individual drug pages for narratives, printable summaries, and therapeutic drug monitoring notes.

Add up to 4 medications

0/4 selected

Browse catalog

Oral Antipsychotics

Second Generation Antipsychotics (SGAs)

First Generation Antipsychotics (FGAs)

Long‑acting Injectable Antipsychotics (LAIs)

Mood Stabilizers

Adjunctive Medications

Ketamine & rapid-acting antidepressants (2)

Benzodiazepines (12)

Sleep & circadian agents (14)

ADHD & wakefulness agents (14)

Substance use treatment & harm reduction (11)

Metabolic & weight management (4)

Other adjunctive medications (17)

Compact view hides Indications, MOA, PK, TDM, Monitoring, and Reviewed.

Medication	Indications (label)	Dosing highlights	MOA	PK	TDM	Risk flags	Monitoring	LAI options	Last reviewed
lithiumMood stabilizerBrands: LITHOBID View labelExact	Acute manic and maintenance treatment of bipolar I disorder. View labelExact	Acute mania: typical starting doses are 600–900 mg/day divided BID/TID, titrated to serum 0.8–1.2 mEq/L (12-hour trough). Typical total daily dose is 1,200–1,800 mg/day.	Modulates second messenger systems; neuroprotective/neurotrophic effects (exact mechanism not fully known).	Not metabolized \| Steady-state mean 24 h	600–1200 ng/mL	Weight	Baseline: BMP (BUN/Cr), electrolytes, TSH, pregnancy test if relevant, weight/BMI. Level timing: 12-hour trough (or pre-morning dose if BID). Level cadence: 5–7 days after each dose change; then every 3–6 months when stable. Lithium levels are typically rechecked after dehydration/illness or when starting or stopping interacting medications (NSAIDs, ACE inhibitors/ARBs, thiazides), often within 5–7 days of the change. Ongoing: Periodic renal and thyroid function, with assessment for toxicity symptoms. Periodic calcium monitoring (hyperparathyroidism risk) and follow-up for urine concentrating symptoms (polyuria/polydipsia) are often part of long-term therapy. Education often emphasizes hydration, consistent salt intake, and key interactions (NSAIDs/ACE inhibitors/diuretics).	No	2025-12-28
valproate (divalproex)Mood stabilizerBrands: DEPAKOTE View labelExact	Acute mania associated with bipolar disorder; seizures (various types). View labelExact	Acute mania: initiate 750–1,000 mg/day (divided TID for DR or once daily ER) and titrate to serum 50–125 µg/mL; loading up to 20–30 mg/kg/day can achieve rapid control.	Increases GABA; modulates voltage-gated sodium and calcium channels.	UGT, beta-oxidation \| Steady-state mean 12 h	50000–125000 ng/mL	Weight Sedation	Baseline: LFTs, CBC with platelets, pregnancy test if relevant, weight/BMI. Level timing: 12-hour trough (extended-release may differ); target 50–125 µg/mL based on clinical context. Ongoing: Periodic LFTs and CBC; monitor metabolic effects and sedation. Precautions: Reinforce teratogenicity counseling; review pancreatitis and hepatotoxicity warnings. Drug interactions: Adjust for enzyme induction (UGT), lamotrigine titration, and other interacting therapies.	No	2025-09-23
aripiprazoleAntipsychoticBrands: ABILIFY View labelExact	Schizophrenia; acute manic or mixed episodes of bipolar I disorder (monotherapy or adjunct to lithium/valproate); maintenance therapy via LAI formulations; adjunctive treatment of major depressive disorder; irritability in autistic disorder; Tourette disorder. View labelExact	Schizophrenia (adults): start 10–15 mg once daily; therapeutic range 10–30 mg/day. Doses above 30 mg rarely add benefit.	Dopamine D2/D3 partial agonist with 5-HT1A partial agonism and 5-HT2A antagonism, stabilizing dopaminergic tone with comparatively low metabolic and EPS burden.	CYP2D6, CYP3A4 \| Steady-state mean 75 h; Steady-state range 75–146 h	120–270 ng/mL	EPS	Metabolic: weight/BMI, fasting glucose/HbA1c, and lipids (baseline and periodic). EPS: monitor akathisia/parkinsonism; periodic AIMS for tardive dyskinesia.	Monthly (q4wk); q4–8wk (varies by strength); Every 2 months (q8wk)	2025-12-28
quetiapineAntipsychoticBrands: SEROQUEL View labelExact	Schizophrenia; acute manic/mixed episodes; bipolar depression; adjunct for major depressive disorder. View labelExact	Schizophrenia (IR): day 1 25 mg BID, titrate to 300–400 mg/day by day 4; maintenance 300–800 mg/day divided BID.	Antagonist at 5‑HT2A and D2 (transient), strong H1 and alpha‑1 activity.	CYP3A4 \| Steady-state mean 6 h	No	Weight Sedation	Metabolic: weight/BMI, fasting glucose/HbA1c, and lipids (baseline and periodic). Sedation: assess next-day impairment and fall risk, especially with other sedatives.	No	2025-09-23

Compare tool FAQ

How many medications can I compare at once?

You can line up to four medications at a time. Use the search box to add or remove drugs, then press “Compare” to refresh the table.

Where does the comparison data come from?

Most fields are generated from our curated facts + per-drug profiles. DailyMed label links come from source metadata, and LAI options come from our LAI catalog.

Can I save or share a comparison?

Yes. The Share button copies a link you can send to teammates, and we store your most recent selection so you can restore it next time you visit.